The clinical evidence

Multiple peer-reviewed case reports describe neonatal abstinence syndrome (NAS) in infants born to mothers who used kratom during pregnancy. The clinical picture is consistent: infants present in the first 24–72 hours after birth with symptoms including irritability, tremors, feeding difficulty, sleep disturbance, vomiting, and in some cases respiratory distress. These cases require NICU monitoring and sometimes pharmacological treatment with morphine or other opioid-receptor-active medications to manage withdrawal — the same protocol used for NAS from prescription opioid exposure.

The pattern reflects kratom's pharmacology. Mitragynine and 7-hydroxymitragynine — kratom's primary alkaloids — are partial mu-opioid receptor agonists. They cross the placenta during pregnancy and produce in-utero opioid receptor activation in the developing fetus. When the maternal supply is interrupted at birth, the newborn experiences classical opioid withdrawal.

For more on kratom's alkaloid pharmacology, see our alkaloid guide.

Kratom and breastfeeding

Mitragynine has been detected in breast milk of nursing mothers who use kratom. Infants nursing from kratom-using mothers can experience drowsiness, feeding difficulty, and withdrawal-like symptoms when feeding patterns change.

Two practical implications:

  1. Mothers who plan to breastfeed should not use kratom during pregnancy or the nursing period
  2. Mothers who have been using kratom and are now breastfeeding should not abruptly stop without consulting their pediatrician — sudden cessation while continuing to nurse can also affect the infant. A supervised approach is essential.

The institutional consensus

Three independent sources align on this guidance:

  • American Kratom Association — explicitly recommends against kratom use during pregnancy and breastfeeding in its consumer guidance and via member vendor labeling requirements
  • OB-GYN clinical consensus — kratom is widely categorized as a substance to avoid in pregnancy due to its mu-opioid receptor activity and documented NAS reports
  • FDA — has issued advisories warning of kratom risks including fetal exposure concerns

Reputable AKA GMP Qualified Vendors include pregnancy warnings on product labels.

If you've been using kratom and discover you're pregnant

Three things, in order:

  1. Disclose to your OB-GYN immediately and honestly. They need to know to monitor pregnancy appropriately and plan for delivery. Concealment puts the infant at risk; disclosure enables appropriate care.
  2. Discuss the right way to discontinue. Depending on how heavy and how recent your use has been, abrupt cessation may not be ideal. Your provider can advise on a tapered approach if appropriate.
  3. Plan for delivery. The delivery team should be informed of kratom exposure so they can monitor the newborn for NAS symptoms and have treatment protocols ready if needed.

Early-pregnancy kratom use before recognition does not necessarily produce lasting harm — many medications and substances used unknowingly in early pregnancy do not. What matters is honest disclosure once recognition occurs and a provider-supervised plan from that point forward.

Why this matters for the kratom community

Kratom advocacy is more credible — and the legal future of natural-leaf kratom is more secure — when the community is honest about the situations where kratom should not be used. Pregnancy is one of the clearest such situations. Vendors who hedge or downplay the pregnancy contraindication are doing the wrong thing for their customers and the wrong thing for the broader category.

At 4 Leaf Herbals, we align fully with the AKA's pregnancy guidance. Our product labels include pregnancy warnings, our marketing copy never suggests kratom use during pregnancy, and we will not knowingly sell to anyone who is pregnant or breastfeeding.

Related considerations

  • Trying to conceive: Discuss with your OB-GYN. Some providers recommend discontinuing kratom in the months before active conception attempts.
  • Postpartum: If breastfeeding, kratom remains contraindicated. If not breastfeeding, postpartum use should still be discussed with your provider, particularly for users on postpartum medications or treatments.
  • IVF and fertility treatments: Discuss with your reproductive endocrinologist. There is limited research on kratom and fertility but conservative provider guidance generally recommends discontinuing.

The bottom line

Kratom should not be used during pregnancy or while breastfeeding. Documented risk of neonatal abstinence syndrome makes this an unambiguous contraindication. If you're considering pregnancy, discontinue kratom and discuss with your OB-GYN. If you're already pregnant and have been using kratom, disclose and follow medical guidance.

For broader kratom safety information, see our comprehensive side effects guide and tolerance and dependence guide.